Possible anti-catatonic effects of minocycline in patients with schizophrenia

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 31, Issue 4, 2007, Pages 968-969

  Ahuja, Niraj ^a   Carroll, Brendan T ^b,c  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF CINCINNATI   (United States)

^c Psychiatry Service   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; ARACHIDONATE 5 LIPOXYGENASE; CHLORTETRACYCLINE; CYTOCHROME C; DEMECLOCYCLINE; DOPAMINE; MINOCYCLINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

ATTENUATION; CATATONIA; CELL STRAIN; CEREBROSPINAL FLUID; DOWN REGULATION; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HYPERACTIVITY; LETTER; MOTOR NEURON DISEASE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; POLYDIPSIA; PSYCHOSIS; SCHIZOPHRENIA; TOXOPLASMOSIS;

CATATONIA; HUMANS; MINOCYCLINE; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA;

EID: 34247566148     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2007.01.018     Document Type: Letter

References (9)

1. Carroll B.T., Thomas C., Jayanti K., Hawkins J.W., and Burbage C. Treating persistent catatonia when benzodiazepines fail. Curr Psych 4 (2005) 56-64
2. Carroll BT, Goforth HW, Thomas C, Ahuja N, McDaniel WW, Kraus MF, et al. Review of Adjunctive Glutamate Antagonist Therapy in the Treatment of Catatonic Syndromes. Journal of Neuropsychiatry and Clinical Neurosciences in press.
3. Claussen C.F., and Claussen E. Antivertiginous action of vitamin B 6 on experimental minocycline-induced vertigo in man. Arzneimittelforschung 38 (1988) 396-399 [Article in German]
4. Jiang S.X., Lertvorachon J., Hou S.T., Konishi Y., Webster J., Mealing G., et al. Chlortetracycline and demeclocycline inhibit calpains and protect mouse neurons against glutamate toxicity and cerebral ischemia. J Biol Chem 280 40 (2005) 33811-33818
5. McCarty M.F. Down-regulation of microglial activation may represent a practical strategy for combating neurodegenerative disorders. Med Hypotheses 67 (2006) 251-269
6. Miyaoka T., Yasukawa R., Yasuda H., Hayashida M., Inagaki T., and Horiguchi J. Possible antipsychotic effects of minocycline in patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 31 (2007) 304-307
7. Northoff G. What catatonia can tell us about "top down modulation": a neuropsychiatric hypothesis. Behav Brain Sci 25 (2002) 555-604
8. Song Y., Wei E.Q., Zhang W.P., Ge Q.F., Liu J.R., Wang M.L., et al. Minocycline protects PC12 cells against NMDA-induced injury via inhibiting 5-lipoxygenase activation. Brain Research 26 1085 (2006) 57-67
9. Tikka T.M., Vartiainen N.E., Goldsteins G., Oja S.S., Andersen P.M., Marklund S.L., et al. Minocycline prevents neurotoxicity induced by cerebrospinal fluid from patients with motor neurone disease. Brain 125 (2002) 722-731